Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION)

This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal doxorubicin) administered concurrent to chemotherapy and in maintenance, in patients with low grade ovarian cancer (including patients with primary peritoneal …

cancer of the ovary
doxorubicin
bevacizumab
fallopian tube
peritoneal cancer
  • 0 views
  • 14 Jul, 2022
  • 2 locations
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer.

platinum-resistant ovarian cancer
niraparib
cancer of the ovary
recurrent cancer
fallopian tube
  • 0 views
  • 25 Oct, 2022
  • 14 locations
HIPEC After Initial CRS in Patients Who Have Received NACT

The majority of women diagnosed with ovarian, fallopian tube and primary peritoneal cancer present with advanced stage III and IV disease. Despite aggressive surgery and systemic chemotherapy, the majority of patients will relapse. Five year survival remains only 20-35% for patients diagnosed with bulky stage IIIC and IV cancers. Patients …

ascites
primary peritoneal carcinoma
cancer of the ovary
intraperitoneal chemotherapy
metastasis
  • 26 views
  • 14 Feb, 2022
  • 1 location
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy

primary peritoneal carcinoma
metastasis
cancer
fallopian tube
tumor cells
  • 63 views
  • 07 Oct, 2022
  • 1 location
BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)

Epithelial ovarian cancer (EOC) is the ninth most common cause of cancer in Australian women, with an estimated 1500 new diagnoses in Australia in 2015, and remains the seventh most common cause of cancer death in Australian women. High grade serous ovarian cancer (HGSC) is the most common form of …

ovarian epithelial carcinoma
vegf
platelet count
cancer
bevacizumab
  • 30 views
  • 14 Feb, 2022
  • 1 location
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help …

primary peritoneal carcinoma
solid tumour
cancer
MRI
fallopian tube
  • 17 views
  • 07 Oct, 2022
  • 1 location
Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian Primary Peritoneal or Fallopian Tube Cancer

This phase II trial the side effects and possible benefits of etigilimab and nivolumab in treating patients with platinum-resistant clear cell ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as etigilimab and nivolumab, may help the body's immune system attack the …

  • 0 views
  • 01 Dec, 2021
  • 1 location
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

This is a phase 2 study whose purpose is to see whether the combination of of pembrolizumab, DPX-Survivac vaccine and low-dose cyclophosphamide has anti-tumor activity in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. DPX-Survivac is an investigational vaccine. A vaccine is a substance that is often …

primary peritoneal carcinoma
line of therapy
cancer
fallopian tube
cancer chemotherapy
  • 57 views
  • 03 Mar, 2022
  • 1 location
High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy

This study aims to evaluate the safety and efficacy of high dose inorganic selenium in preventing and relieving chemotherapy-induced peripheral neuropathy (CIPN) in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer patients. This study will be conducted as a phase III randomized controlled trial in platinum-sensitive recurrent ovarian, fallopian, or …

ovarian epithelial carcinoma
primary peritoneal carcinoma
cancer
bevacizumab
carboplatin
  • 1 views
  • 24 Jan, 2021
  • 1 location
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

ovarian epithelial carcinoma
bevacizumab
cancer of the ovary
ovarian cancer
  • 0 views
  • 04 Oct, 2022
  • 3 locations